Introduction
Thrombospondin (TSP)' is a major glycoprotein located in the a-granules of human platelets (1, 2) . TSP is a 450-kD protein and is composed of three disulfide-linked subunits (3, 4) . It is secreted upon thrombin stimulation and binds to the platelet membrane in the presence of calcium (5) . During the process of aggregation, thrombin-stimulated platelets develop a membrane-bound lectin activity that originates from a-granules and appears to play an important role in mediating platelet aggregation by binding to a specific receptor on adjacent platelets (6, 7) . Fibrinogen is the receptor for the platelet lectin (8) . We have recently found that TSP has hemagglutinating (lectin-like) activity and specifically binds fibrinogen, suggesting that TSP may be similar to the previously identified platelet lectin and may participate in the platelet aggregation process (9, 10) .
In addition to platelets, TSP is found in other cell systems. Both cultured human umbilical vein endothelial cells and bovine aortic endothelial cells synthesize and secrete large amounts of TSP (11, 12) . Cultured human fibroblasts and aortic smooth muscle cells also synthesize and secrete TSP and incorporate it into extracellular matrix (13, 14) . The incorporation by fibroblasts of TSP into extracellular matrix is reminiscent of the role of fibronectin (14) . A specific interaction of TSP with fibronectin and collagen has been demonstrated (10, 15) . These data suggest that TSP may have multiple functions. In addition to its role in platelet aggregation, TSP may play a role in the formation and organization of the extracellular matrix and in cell-cell and cell-matrix interactions.
Histidine-rich glycoprotein (HRGP) is an a2-glycoprotein in human plasma (16, 17) of apparently diverse biological functions. HRGP interacts with several divalent metals, suggesting that HRGP may have a role in the transport or homeostasis of metals in vivo (18, 19) . HRGP interacts with the high affinity lysine-binding site of plasminogen (20) , which mediates the binding of plasmin(ogen) to fibrin and of plasmin(ogen) to a2-plasmin inhibitor (21) . By reducing the binding of plasminogen to fibrin, HRGP may represent a physiological counterpart of antifibrinolytic amino acids, such as 6-aminohexanoic acid, which results in an antifibrinolytic effect. More recently, HRGP was found to interact strongly with heparin, resulting in neutralization of the anticoagulant activity of heparin (22) . HRGP, therefore, may play a role in the modulation ofthe anticoagulant properties of heparin in plasma. HRGP is also immunochemically identical with a serum factor that inhibits autorosette formation between erythrocytes and peripheral lymphocytes; this suggests that HRGP may modulate the immune responses of lymphocytes (23) . We have recently found that HRGP is present in human platelets and is released following thrombin stimulation (24) . In this study, we present evidence demonstrating specific complex formation between HRGP and TSP. The complex contained heparin-binding and neutralizing activity. (3) , as previously described (10) . The isolation and purification of Factor VIII Related:antigen (VIIIR:Ag), fibronectin, a2-plasmin inhibitor, antithrombin III, and platelet membrane glycoproteins (GP) lIb and i11a have been described in detail (25) (26) (27) (28) . Factor X was a generous gift from Dr Antisera. Antisera to the purified HRGP were raised in rabbits by using methods previously described (25) . Insolubilized HRGP-depleted plasma was used to remove traces of contaminating antibodies from the HRGP antisera. HRGP-depleted plasma was prepared by utilizing the fibrinogen-depleted plasma supernatant as detailed above for the purification of HRGP. The supernatant was mixed with CM-cellulose 52 (1 g/40 ml supernatant) for I h and the resin removed by centrifugation. This adsorption step was repeated and a portion of the supernatant was coupled to Sepharose beads. The absorbed HRGP antisera produced a single precipitin arc when diffused against human serum and yielded a reaction of immunologic identity between serum and the purified HRGP. y-globulin fractions of the absorbed anti-HRGP sera and normal rabbit sera were prepared as previously described (25 (10, 29) . Briefly, microtitration plates were coated with purified TSP by incubating TSP (0.2 ml) in the bicarbonatecoating buffer (15 mM Na2CO3, 35 mM NaHCO3, pH 9.6,0.02% NaN3) for 3 h at 37°C. The wells were washed three times with Tris-Tween buffer (0.01 M Tris-HCl, 0.15 M NaCl, 0.05% Tween 20, pH 7.4). Purified HRGP diluted in Tris-Tween buffer was added in duplicate to coated wells for 18 h at 4°C. The washing procedure was repeated and alkaline phosphatase-conjugated, immunopurified anti-HRGP IgG (1:800 dilution) was added for 3 h at 37°C. After washing, the substrate pnitrophenyl phosphate was added and color development was followed by repeated readings at 405 nm in a Titertek multiscan photometer. The formation of the TSP-HRGP complex was expressed as the enzymatic activity of the bound alkaline phosphatase (AA405 min-'). For the double antibody ELISA, anti-TSP IgG (8 gg/ml) in coating buffer was applied to the plastic wells for 3 h at 37°C. After washing, TSP (4 ,ug/ml) in Tris-Tween buffer was added for 4 h at 37°C. The washing step was repeated, and HRGP in Tris-Tween buffer was added and the remaining steps were carried out as described above.
Methods
Determination ofprotein-coating efficiency on microtitration plates. Purified human plasma HRGP was labeled with 1251 by using the modified chloramine T method (30) . Microtitration plates were coated in duplicate with 0.2-ml portions of labeled HRGP at different concentrations in the bicarbonate-coating buffer for 3 h at 370C. After washing three times with Tris-Tween buffer, each well was cut out, the radioactivity of the coated protein counted, and the coating efficiency of HRGP at different concentrations determined. The coating efficiency of TSP has been determined in previous studies (10) .
Sucrose-density-gradient ultracentrifugation. TSP and HRGP were incubated in 10 mM Tris-HCl, 0.15 M NaCI, pH 7.4, with 1 mM Ca"+ for 1 h at 370C. 0.2-ml aliquot of the incubation mixture was layered on top of a 10-40% linear sucrose gradient (5 ml) in the same buffer and centrifuged at 165,000 g for 18 h at 4VC in a SW65 rotor (Beckman Instruments Inc., Fullerton, CA). The gradient was fractionated by collecting eight drop-fractions, and an aliquot (0.16 ml) of each fraction was coated onto the microtitration well by incubating at 4VC for 18 h. TSP and HRGP in each fraction were detected and quantified by the corresponding specific ELISA. The following proteins were used for calibration: thyroglobulin, S20w = 19; catalase, S20w = 11.3; human serum albumin, S20w = 4.6. Linearity of the sucrose gradients was confirmed by measuring the refractive indices of alternating fractions.
3S-heparin-binding studies. Purified HRGP, TSP, and albumin
were coupled separately to CNBR-activated Sepharose 4B beads as described (31) . An aliquot of TSP coupled beads was incubated with HRGP at 1 mg/ml for 1 h at 370C. The beads were washed extensively with Tris-Tween buffer and then incubated with 100,000 dpm (0.045 AtCi) "5S-heparin (sp act 0.015 uCi/hg) in 20 mM Tris-HCl, 0.15 M NaCl, 2 mM CaCI2, pH 7.4, for 1 h at 37°C. The beads were washed five times with Tris-Tween buffer containing 2 mM CaCl2. 35S-heparin was eluted from the beads by boiling in 2% sodium dodecyl sulfate for 10 min and counted in a liquid scintillation counter.
Thrombin time assays. The influence of the TSP-HRGP complex on the neutralization ofheparin in plasma was evaluated by determination of thrombin times of normal plasma, plasma depleted in HRGP, and the depleted plasma in the presence of TSP beads preincubated with HRGP. 0.2 ml of plasma (diluted one-half with water), and 0.1 ml of beads (or buffer) were incubated in the presence of clinical grade heparin (0.25 unit/ml final concentration) for 20 min at 37°C. 0.1 ml ofthrombin solution (-0.2 NIH units/ml final concentration) was added and the clotting time recorded. Thrombin times reported represent mean values of at least two separate measurements. HRGP-depleted plasma was prepared by repeated absorption of normal plasma with CM-cellulose 52 as described above.
Results
ELISA of purified plasma HRGP. A specific ELISA for the detection and quantification ofplasma HRGP was developed. HRGP in increasing concentrations was passively adsorbed to the wells of a microtitration plate. Affinity-purified, monospecific, anti-HRGP IgG which was directly conjugated with alkaline phosphatase (1:800 dilution) was added. The resulting hydrolysis of the substrate p-nitrophenyl phosphate was linear with the concentration of HRGP added to the well up to 1,000 ng/ml. By using '251I-labeled HRGP, the actual amount of HRGP bound to the plastic well was determined at each concentration of protein added and this was correlated with the color generated in the ELISA (Fig. 1) . No differences in reactivity with specific antibody were noted when nonlabeled HRGP was compared with '251-labeled HRGP. HRGP (pg/ml) Figure 2 . ELISA detection of TSP-HRGP complex formation. TSP at three concentrations in coating buffer was applied to the plastic wells for 3 h at 37°C. After washing, HRGP at various concentrations in Tris-Tween buffer was added for 18 h at 4°C. After washing, alkaline phosphatase-conjugated anti-HRGP IgG and the enzyme substrate were sequentially added as described in Fig. 1.   7 Thrombospondin-Histidine-rich Glycoprotein Interaction Incubation time Figure 3 . Time course study of TSP-HRGP complex formation. TSP (4 ,g/ml) in coating buffer was applied to the plastic wells for 3 h at 370C. After washing, HRGP (2 ug/ml) in Tris-Tween buffer was added for various periods of incubation time (hours). The remaining steps were carried out as described in Fig. 1 .
To study the time course of the HRGP binding to adsorbed TSP, complex formations with different incubation time periods were determined (Fig. 3) . Maximum binding occurred at 3 h of incubation at 4VC.
Since HRGP binds heparin (17, 22) , and TSP isolation involves heparin-Sepharose affinity chromatography, the possibility was raised whether the observed TSP-HRGP interaction might be due to HRGP binding to a trace amount of heparin in the adsorbed TSP sample. Adsorbed TSP was incubated with enzymatically active heparinase (0.1 U/ml) prior to the addition of HRGP. There was no decrease in the binding of HRGP to the heparinase-treated, adsorbed TSP. Alternatively, TSP was preincubated with heparinase before adsorption to the plastic plate. No decrease in the HRGP binding was noted. The activity of heparinase was demonstrated by its ability to abolish the prolongation ofthe plasma thrombin time by 0.1 U/ml heparin.
Specificity ofthe TSP-HRGP complexformation. To demonstrate the specificity of the TSP-HRGP interaction, competitive inhibition studies of the TSP-HRGP complex formation 100 by excess fluid-phase TSP were carried out. Following the coating of TSP (4 yg/ml) on the microtitration plate, HRGP (1 ug/ml and 2 ,ug/ml) was incubated in Tris-Tween buffer in the presence of increasing concentrations ofTSP. 50% inhibition of the complex formation was achieved by 1.5 ,ug/ml TSP (3.6 nM) (Fig.  4) . The small amount of HRGP which complexed to adsorbed TSP in the presence of excess soluble TSP (-15%) was considered "nonspecific" binding. No significant inhibition of HRGP complex formation with TSP was detected by excess fluid-phase albumin or fibrinogen.
The specificity of the HRGP interaction with adsorbed TSP was studied further by incubating fluid-phase HRGP with other adsorbed proteins (Fig. 5) . Minimal complex formation was detected with purified VIIIR:Ag, fibronectin, and antithrombin III. Previous studies using 1251I-radiolabeled proteins had shown that the coating efficiency for VIIIR:Ag and fibronectin on the microtitration plate was comparable with that of TSP (10 (Table I ). The binding of HRGP to the antibody-immobilized TSP was also concentration dependent with maximal binding occurring at 1 qg/ml.
The amount of complex formation demonstrated by using the double-antibody ELISA was less than that detected when HRGP was added to TSP coated directly on the microtitration plate (Fig. 2) . By using '251I-radiolabeled TSP, the amount of TSP immobilized on the anti-TSP coated plate was determined to be 32.8 ng, which was significantly less than the amount of TSP coated directly on the plate (262.7 ng).
Sucrose-density-gradient ultracentrifugation of TSP-HRGP complexes. Sucrose-density-gradient ultracentrifugation was used to assess whether HRGP and TSP formed a complex in the fluid phase. Purified plasma HRGP showed a single peak of reactivity with a sedimentation coefficient of 3.2 S, which is in good agreement with the published value (1 7) (Fig. 6) . When a mixture of HRGP and TSP (at a molar ratio of 3:1) was analyzed, there was a significant shift of the HRGP peak from 3.2S to I1.8S, demonstrating the formation of TSP-HRGP complexes in the fluid phase. Purified TSP showed a major peak with a sedimentation coefficient of 9S, which is also in good agreement with the published sedimentation coefficient for TSP (4, 32) (Fig. 7) . In addition, a minor peak with a higher sedimentation coefficient was noted, which possibly represents multimeric forms of TSP. When a mixture of HRGP and TSP was analyzed, there was a significant shift of the TSP peak from 9S to 11.8S. A relatively minor peak with a higher sedimentation coefficient was also noted, suggesting a heterogeneity of the TSP-HRGP complexes. Assuming that the partial specific volumes for TSP and the TSP-HRGP complex are similar, an approximate estimation of the molecular weight of the complex was obtained from the sedimentation coefficients. (Table II) . Similarly, the binding of fibrinogen to adsorbed TSP was not affected by the presence or absence of HRGP. Fract ions Figure 6 . Sucrose-density-gradient ultracentrifugation of HRGP and TSP. HRGP, either alone or together with TSP (molar ratio of 3 HRGP: 1 TSP), was incubated in 10 mM Tris-HCl, 0.15 M NaCL, pH 7.4, with 1 mM Ca++ for 1 h at 37°C. 0.2-ml aliquots of the incubation mixtures were layered on separate 10-40% linear sucrose gradients (5 ml each) in the same buffer and sedimented at 165,000 g for 18 h at 4°C. The gradients were fractionated by collecting 8-drop fractions and an aliquot (0.16 ml) of each fraction was coated onto the microtitration well by incubating at 4°C for 18 h. HRPG in each fraction was quantified by the specific ELISA for HRGP. The arrows in the top panel corresponded to the three proteins used for calibration: thyroglobulin S20W = 19; catalase, S20W = 11.3; and human serum albumin, S20w = 4.6. Fractions Figure 7 . Sucrose-density-gradient ultracentrifugation of HRGP and TSP. TSP, either alone or together with HRGP (molar ratio of 7 HRGP: 1 TSP), was analyzed as described in Fig. 7 except that a specific ELISA for TSP was used for detection of TSP in each fraction of the gradients.
Heparin binding by TSP-HRGP complex. Recent studies demonstrate that HRGP interacts strongly with heparin both in purified systems and in plasma, resulting in neutralization of the anticoagulant activity of heparin (22) . To determine whether HRGP complexed to TSP binds heparin, purified TSP was coupled to cyanogen bromide-activated Sepharose 4B beads. The TSP coupled beads were incubated with purified plasma HRGP. 35S-heparin binding to the TSP-HRGP complex on the beads was determined (Table III) . The amount of heparin bound to TSP beads preincubated with HRGP was significantly greater than that bound to TSP beads alone, indicating that HRGP complexed with TSP retains the heparin-binding property. By using the specific ELISA for HRGP, the amount of HRGP complexed to TSP on the beads was determined to be 50 ng HRGP/50 Ml beads. Therefore, 50 ng HRGP specifically bound 20.55 ng heparin (Table III) . Assuming a Mr of 16,500 for heparin, the data suggests a stoichiometry of HRGP-heparin complex formation of 1:1.5, which is in good agreement with recent published data (22) . Control studies using HRGP-coupled beads showed significant heparin binding while albumin-coupled beads did not, demonstrating the specificity of heparin binding.
To determine whether HRGP complexed with TSP neutralized the anticoagulant activity ofheparin in plasma, thrombin time assays were performed (Table IV) . HRGP-depleted plasma had a normal thrombin time in the absence of heparin but showed a markedly prolonged thrombin time in the presence (Fig. 7) . Our recent finding that TSP has hemagglutinating activity is consistent with the concept that TSP is multivalent (9) . Electron microscopic studies have demonstrated that TSP has three to four well-defined nodular domains connected by flexible regions (32) . It (Fig. 2) . It is possible that TSP adsorbed on the plastic surface has an altered affinity for HRGP and this may not represent an accurate estimation of KD. However, it should be noted that the competitive inhibition studies by fluid-phase TSP (Fig. 4) , as well as the distribution of the free and bound HRGP in the sucrose-gradient ultracentrifugation analysis (Fig. 6) , suggest that the native TSP molecule has a high affinity for HRGP in the fluid phase.
We have previously demonstrated that adsorbed TSP formed a complex with fibrinogen and to a lesser extent with fibronectin (10), suggesting that TSP may play an important role in the platelet aggregation process. In this study, fibrinogen did not inhibit complex formation of HRGP with TSP and conversely, HRGP did not interfere with fibrinogen binding to adsorbed TSP (Table II) The biological significance of the TSP-HRGP interaction remains to be fully defined. Thrombin-stimulated platelets release TSP from the a-granule, which binds to the activated platelet surface in the presence of Ca". HRGP is also present in human platelets and is released following thrombin stimulation (24) . Our studies suggest the possibility that plasma HRGP, as well as platelet HRGP, if both proteins have the same functional capabilities, may interact specifically with TSP on the activated platelet surface and regulate heparin action. In addition, since HRGP interacts with the high affinity lysine-binding site of plasminogen (20) , the specific binding of HRGP to TSP on the platelet surface may also serve to localize plasminogen onto the activated platelet surface and modulate fibrinolysis in the microenvironment of the platelet plug. Thus, the TSP-HRGP complex in a focal area of active hemostasis and thrombosis could serve as a prothrombotic mediator leading to an increased deposition of fibrin.
It is of great interest that in addition to platelets, TSP has been demonstrated in human endothelial cells, fibroblasts, and smooth muscle cells (1 [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . Recent studies suggest that a serum factor that inhibits autorosette formation of murine thymocytes and peripheral lymphocytes is immunochemically similar to HRGP (23) . Whether specific TSP-HRGP complex formation plays a role in the cell-cell interaction between these various cellular systems is a subject for further study.
